Menopause symptoms are common, disruptive, and treatable. Too many women still live with them without a plan.

On October 15, 2026, the American College of Obstetricians and Gynecologists (ACOG) published Clinical Practice Guideline No. 13, Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. It replaces guidance from 2014 and covers hormonal, nonhormonal, and nonpharmacologic treatment.

For the American College of Osteopathic Obstetricians and Gynecologists (ACOOG), the guideline reinforces a principle osteopathic physicians practice every day. Treat the whole person. Ask about every symptom. Offer every evidence-based option.

Source: ACOG Clinical Practice Guideline No. 13, 2026.

Many patients never mention their symptoms. Some assume nothing helps. Others hear their symptoms dismissed as part of aging.

The guideline calls for earlier and more complete patient education so women recognize perimenopause and seek care sooner. Physicians set the tone. Ask every midlife patient about hot flashes, sleep, and mood at each annual visit, and treat the answers as clinical information worth acting on.

The guideline strongly recommends systemic menopausal hormone therapy (MHT) for hot flashes, night sweats, and related sleep disruption in patients without contraindications. Patients with a uterus need estrogen plus a progestogen. Patients without a uterus use estrogen alone.

Timing matters. When a patient chooses MHT, the guideline recommends starting before age 60 or within 10 years of natural menopause. After this window, baseline risks of blood clots, stroke, and coronary heart disease rise, and the decision calls for an individualized approach.

Outdated fears still steer many of these decisions. In 2025, the U.S. Food and Drug Administration (FDA) recommended removing boxed warnings for cardiovascular disease, breast cancer, and probable dementia from MHT labeling. The guideline also notes nearly two-thirds of Women's Health Initiative participants were 60 or older, which limits how well those findings apply to younger women near menopause. Shared decision-making, grounded in each patient's age, history, risks, and goals, leads the way.

Some patients have contraindications. Others prefer to avoid hormones. Every patient deserves an effective treatment, and the guideline outlines several.

The guideline conditionally recommends cognitive behavioral therapy (CBT), mindfulness-based interventions, exercise, clinical hypnosis, and acupuncture for vasomotor, sleep, and mood symptoms. It generally pairs these approaches with medication.

This approach fits the osteopathic model of care. Sleep, movement, stress, and mood affect one another. A treatment plan built around all four serves the patient better than a prescription alone.

Access to menopause care remains uneven. In the Study of Women's Health Across the Nation (SWAN), Black women reported a higher symptom burden than White women and were less likely to receive treatment.

Consistent screening narrows this gap. When every patient hears the same questions and the same full range of options, fewer women fall through. Insurance coverage for evidence-based treatment matters too, especially as misinformation about menopause spreads online.

ACOG plans separate guidance on the genitourinary syndrome of menopause (GSM) in 2027. Vaginal dryness and urinary symptoms affect quality of life as much as hot flashes do. ACOOG will share updates and education as this guidance arrives.